Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 25 | 2026 | 334 | 9.800 |
Why?
|
| Neonatal Screening | 6 | 2026 | 207 | 2.040 |
Why?
|
| Recombinases | 3 | 2025 | 28 | 1.100 |
Why?
|
| Spleen | 3 | 2024 | 258 | 1.070 |
Why?
|
| Fever | 2 | 2020 | 312 | 0.890 |
Why?
|
| Pneumococcal Vaccines | 1 | 2024 | 174 | 0.740 |
Why?
|
| Delphi Technique | 1 | 2024 | 283 | 0.740 |
Why?
|
| Hematologic Diseases | 1 | 2023 | 82 | 0.740 |
Why?
|
| Splenomegaly | 2 | 2024 | 32 | 0.710 |
Why?
|
| Anesthesia, Conduction | 1 | 2022 | 19 | 0.710 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 18 | 0.690 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2024 | 229 | 0.680 |
Why?
|
| Hemoglobinopathies | 2 | 2023 | 14 | 0.640 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 146 | 0.630 |
Why?
|
| Malaria | 2 | 2020 | 93 | 0.630 |
Why?
|
| Ketamine | 1 | 2023 | 206 | 0.630 |
Why?
|
| Antimalarials | 2 | 2020 | 40 | 0.610 |
Why?
|
| Spherocytosis, Hereditary | 1 | 2019 | 6 | 0.600 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 570 | 0.600 |
Why?
|
| Nucleic Acid Amplification Techniques | 3 | 2025 | 69 | 0.580 |
Why?
|
| Splenectomy | 1 | 2019 | 61 | 0.580 |
Why?
|
| Laboratories | 1 | 2019 | 81 | 0.570 |
Why?
|
| Stroke | 2 | 2023 | 1061 | 0.530 |
Why?
|
| Developing Countries | 1 | 2020 | 305 | 0.530 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 694 | 0.510 |
Why?
|
| Sickle Cell Trait | 2 | 2015 | 10 | 0.510 |
Why?
|
| Hydroxyurea | 3 | 2025 | 89 | 0.490 |
Why?
|
| GATA2 Transcription Factor | 1 | 2016 | 46 | 0.470 |
Why?
|
| Humans | 35 | 2026 | 131163 | 0.470 |
Why?
|
| Plasmodium yoelii | 1 | 2015 | 2 | 0.470 |
Why?
|
| Trophozoites | 1 | 2015 | 2 | 0.470 |
Why?
|
| Plasmodium knowlesi | 1 | 2015 | 3 | 0.470 |
Why?
|
| Africa South of the Sahara | 3 | 2026 | 121 | 0.460 |
Why?
|
| Infant, Newborn | 10 | 2026 | 8635 | 0.460 |
Why?
|
| Acetamides | 1 | 2015 | 43 | 0.450 |
Why?
|
| Thalassemia | 1 | 2015 | 9 | 0.450 |
Why?
|
| Plasmodium falciparum | 1 | 2015 | 81 | 0.440 |
Why?
|
| Haploinsufficiency | 1 | 2016 | 266 | 0.420 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 159 | 0.420 |
Why?
|
| Neutropenia | 1 | 2015 | 209 | 0.400 |
Why?
|
| Child | 13 | 2024 | 26341 | 0.400 |
Why?
|
| Thrombocytopenia | 2 | 2024 | 223 | 0.400 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2022 | 1280 | 0.400 |
Why?
|
| Caregivers | 1 | 2019 | 598 | 0.400 |
Why?
|
| Monitoring, Physiologic | 1 | 2015 | 376 | 0.370 |
Why?
|
| Antisickling Agents | 2 | 2025 | 20 | 0.370 |
Why?
|
| Pain | 3 | 2023 | 450 | 0.360 |
Why?
|
| Child, Preschool | 7 | 2025 | 15110 | 0.310 |
Why?
|
| Alleles | 3 | 2025 | 1673 | 0.310 |
Why?
|
| Female | 17 | 2026 | 70963 | 0.300 |
Why?
|
| Quality Improvement | 1 | 2015 | 722 | 0.290 |
Why?
|
| beta-Globins | 2 | 2025 | 9 | 0.280 |
Why?
|
| Africa | 2 | 2019 | 135 | 0.280 |
Why?
|
| Globins | 1 | 2007 | 20 | 0.260 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 2596 | 0.260 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2007 | 13 | 0.260 |
Why?
|
| Thrombasthenia | 1 | 2007 | 2 | 0.260 |
Why?
|
| GATA1 Transcription Factor | 1 | 2007 | 10 | 0.250 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 546 | 0.250 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2007 | 29 | 0.250 |
Why?
|
| Anemia, Aplastic | 1 | 2007 | 60 | 0.240 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2007 | 81 | 0.240 |
Why?
|
| Hemoglobins | 2 | 2019 | 286 | 0.230 |
Why?
|
| Infant | 6 | 2025 | 13352 | 0.220 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 262 | 0.210 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2024 | 21 | 0.210 |
Why?
|
| Blood Platelets | 1 | 2007 | 313 | 0.210 |
Why?
|
| Benzaldehydes | 2 | 2023 | 13 | 0.200 |
Why?
|
| Immunoglobulin M | 1 | 2024 | 210 | 0.200 |
Why?
|
| Morphine | 1 | 2023 | 81 | 0.200 |
Why?
|
| Hemorrhage | 1 | 2007 | 487 | 0.190 |
Why?
|
| Male | 11 | 2026 | 64957 | 0.190 |
Why?
|
| Life Expectancy | 1 | 2023 | 63 | 0.190 |
Why?
|
| Pyrazines | 2 | 2023 | 81 | 0.190 |
Why?
|
| Infusions, Intravenous | 1 | 2024 | 531 | 0.190 |
Why?
|
| Analgesics | 1 | 2023 | 120 | 0.190 |
Why?
|
| Patient Care | 1 | 2023 | 98 | 0.190 |
Why?
|
| Mutation, Missense | 1 | 2007 | 919 | 0.180 |
Why?
|
| Acute Chest Syndrome | 1 | 2021 | 14 | 0.180 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2021 | 29 | 0.180 |
Why?
|
| Pneumococcal Infections | 1 | 2024 | 281 | 0.170 |
Why?
|
| Consensus | 1 | 2024 | 512 | 0.170 |
Why?
|
| Adolescent | 5 | 2024 | 20987 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 981 | 0.170 |
Why?
|
| Pyrazoles | 2 | 2023 | 349 | 0.160 |
Why?
|
| Neoplasms | 1 | 2015 | 3016 | 0.160 |
Why?
|
| Heart Transplantation | 1 | 2007 | 800 | 0.160 |
Why?
|
| Sensitivity and Specificity | 2 | 2025 | 2085 | 0.150 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 239 | 0.150 |
Why?
|
| Prevalence | 1 | 2026 | 2701 | 0.150 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 500 | 0.150 |
Why?
|
| Cytokines | 1 | 2025 | 1339 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2023 | 1064 | 0.140 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 214 | 0.140 |
Why?
|
| Parents | 1 | 2025 | 1128 | 0.130 |
Why?
|
| Endemic Diseases | 1 | 2017 | 60 | 0.130 |
Why?
|
| Mothers | 1 | 2019 | 388 | 0.120 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2025 | 2833 | 0.120 |
Why?
|
| Liberia | 1 | 2016 | 9 | 0.120 |
Why?
|
| Isoelectric Focusing | 1 | 2016 | 22 | 0.120 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2015 | 15 | 0.120 |
Why?
|
| Host-Parasite Interactions | 1 | 2015 | 72 | 0.110 |
Why?
|
| Biological Transport | 1 | 2015 | 329 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2015 | 186 | 0.110 |
Why?
|
| Hematologic Tests | 1 | 2015 | 36 | 0.110 |
Why?
|
| Solubility | 1 | 2015 | 117 | 0.110 |
Why?
|
| Young Adult | 3 | 2024 | 10103 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2007 | 3147 | 0.110 |
Why?
|
| Water | 1 | 2015 | 186 | 0.110 |
Why?
|
| Macaca mulatta | 1 | 2015 | 504 | 0.100 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2015 | 318 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 2904 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 1295 | 0.100 |
Why?
|
| Blood Transfusion | 1 | 2015 | 294 | 0.100 |
Why?
|
| Retrospective Studies | 2 | 2023 | 17753 | 0.090 |
Why?
|
| Incidence | 2 | 2022 | 3360 | 0.090 |
Why?
|
| Risk | 1 | 2015 | 726 | 0.090 |
Why?
|
| Quality of Life | 1 | 2022 | 2082 | 0.090 |
Why?
|
| Global Health | 1 | 2017 | 626 | 0.090 |
Why?
|
| Pilot Projects | 1 | 2016 | 1445 | 0.090 |
Why?
|
| Hemolysis | 2 | 2023 | 86 | 0.080 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 1490 | 0.080 |
Why?
|
| Risk Assessment | 1 | 2019 | 3711 | 0.080 |
Why?
|
| Pregnancy | 1 | 2021 | 7512 | 0.070 |
Why?
|
| Electronic Health Records | 1 | 2015 | 844 | 0.070 |
Why?
|
| Exchange Transfusion, Whole Blood | 1 | 2007 | 11 | 0.070 |
Why?
|
| Cholecystitis | 1 | 2007 | 20 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2007 | 101 | 0.060 |
Why?
|
| Cholecystectomy | 1 | 2007 | 55 | 0.060 |
Why?
|
| United States | 1 | 2023 | 12072 | 0.060 |
Why?
|
| Parvoviridae Infections | 1 | 2007 | 31 | 0.060 |
Why?
|
| Cardiomyopathy, Restrictive | 1 | 2007 | 21 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2007 | 60 | 0.060 |
Why?
|
| Erythrocytes, Abnormal | 1 | 2007 | 12 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2007 | 44 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2025 | 5196 | 0.060 |
Why?
|
| Pleural Effusion | 1 | 2007 | 103 | 0.060 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2007 | 102 | 0.060 |
Why?
|
| Cytoplasmic Granules | 1 | 2007 | 50 | 0.060 |
Why?
|
| Prednisone | 1 | 2007 | 235 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2007 | 148 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2007 | 352 | 0.060 |
Why?
|
| Chromosomes, Human, X | 1 | 2007 | 155 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 4738 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2015 | 5063 | 0.060 |
Why?
|
| Rituximab | 1 | 2007 | 170 | 0.060 |
Why?
|
| Amino Acid Substitution | 1 | 2007 | 405 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 6196 | 0.060 |
Why?
|
| Heterozygote | 1 | 2007 | 737 | 0.050 |
Why?
|
| Abdominal Pain | 1 | 2007 | 319 | 0.050 |
Why?
|
| Prospective Studies | 1 | 2015 | 6459 | 0.050 |
Why?
|
| Immunoassay | 1 | 2025 | 126 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1153 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2007 | 509 | 0.050 |
Why?
|
| Failure to Thrive | 1 | 2024 | 86 | 0.050 |
Why?
|
| Syndrome | 1 | 2007 | 1155 | 0.050 |
Why?
|
| Autoantibodies | 1 | 2007 | 451 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2025 | 414 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2019 | 12936 | 0.050 |
Why?
|
| Coronary Disease | 1 | 2007 | 624 | 0.050 |
Why?
|
| Recurrence | 1 | 2007 | 1489 | 0.050 |
Why?
|
| Point Mutation | 1 | 2024 | 333 | 0.050 |
Why?
|
| Pedigree | 1 | 2007 | 1677 | 0.050 |
Why?
|
| Bilirubin | 1 | 2023 | 126 | 0.050 |
Why?
|
| Nigeria | 1 | 2022 | 71 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 223 | 0.040 |
Why?
|
| Cardiomyopathies | 1 | 2007 | 514 | 0.040 |
Why?
|
| Program Evaluation | 1 | 2022 | 447 | 0.040 |
Why?
|
| Polymerization | 1 | 2019 | 12 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2007 | 999 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2019 | 59 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2024 | 1882 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2025 | 919 | 0.030 |
Why?
|
| Mice | 1 | 2015 | 18301 | 0.030 |
Why?
|
| Qualitative Research | 1 | 2022 | 730 | 0.030 |
Why?
|
| Adult | 3 | 2025 | 31282 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 1173 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1618 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2019 | 1626 | 0.030 |
Why?
|
| Heart Defects, Congenital | 1 | 2007 | 1889 | 0.030 |
Why?
|
| Animals | 1 | 2015 | 33912 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 3385 | 0.020 |
Why?
|
| Middle Aged | 1 | 2019 | 28601 | 0.010 |
Why?
|